Annual CFF
-$535.70 M
-$1.02 B-211.33%
31 December 2023
Summary:
Emergent BioSolutions annual cash flow from financing activities is currently -$535.70 million, with the most recent change of -$1.02 billion (-211.33%) on 31 December 2023. During the last 3 years, it has fallen by -$605.20 million (-870.79%). EBS annual CFF is now -167.92% below its all-time high of $788.70 million, reached on 31 December 2018.EBS Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
-$180.30 M
-$129.40 M-254.22%
30 September 2024
Summary:
Emergent BioSolutions quarterly cash flow from financing activities is currently -$180.30 million, with the most recent change of -$129.40 million (-254.22%) on 30 September 2024. Over the past year, it has dropped by -$137.30 million (-319.30%). EBS quarterly CFF is now -122.94% below its all-time high of $785.90 million, reached on 31 December 2018.EBS Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
-$185.80 M
-$137.30 M-283.09%
30 September 2024
Summary:
Emergent BioSolutions TTM cash flow from financing activities is currently -$185.80 million, with the most recent change of -$137.30 million (-283.09%) on 30 September 2024. Over the past year, it has increased by +$1.50 million (+0.80%). EBS TTM CFF is now -122.40% below its all-time high of $829.30 million, reached on 30 June 2019.EBS TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EBS Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -211.3% | -319.3% | +0.8% |
| 3 y3 years | -870.8% | -3506.0% | -458.0% |
| 5 y5 years | -167.9% | -815.2% | -123.0% |
EBS Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -211.3% | at low | -151.1% | +63.0% | -134.3% | +65.3% |
| 5 y | 5 years | -167.9% | at low | -151.1% | +63.0% | -123.0% | +65.3% |
| alltime | all time | -167.9% | at low | -122.9% | +63.0% | -122.4% | +65.3% |
Emergent BioSolutions Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$180.30 M(+254.2%) | -$185.80 M(+283.1%) |
| June 2024 | - | -$50.90 M(-225.1%) | -$48.50 M(-90.0%) |
| Mar 2024 | - | $40.70 M(+766.0%) | -$484.50 M(-9.6%) |
| Dec 2023 | -$535.70 M(-211.3%) | $4.70 M(-110.9%) | -$535.70 M(+186.0%) |
| Sept 2023 | - | -$43.00 M(-91.2%) | -$187.30 M(-320.4%) |
| June 2023 | - | -$486.90 M(+4537.1%) | $85.00 M(-84.3%) |
| Mar 2023 | - | -$10.50 M(-103.0%) | $541.20 M(+12.5%) |
| Dec 2022 | $481.20 M(-441.3%) | $353.10 M(+54.0%) | $481.20 M(+2558.6%) |
| Sept 2022 | - | $229.30 M(-846.9%) | $18.10 M(-108.4%) |
| June 2022 | - | -$30.70 M(-56.5%) | -$216.20 M(+14.2%) |
| Mar 2022 | - | -$70.50 M(-35.9%) | -$189.30 M(+34.3%) |
| Dec 2021 | -$141.00 M(-302.9%) | -$110.00 M(+2100.0%) | -$141.00 M(+323.4%) |
| Sept 2021 | - | -$5.00 M(+31.6%) | -$33.30 M(-156.6%) |
| June 2021 | - | -$3.80 M(-82.9%) | $58.80 M(-12.6%) |
| Mar 2021 | - | -$22.20 M(+865.2%) | $67.30 M(-3.2%) |
| Dec 2020 | $69.50 M(-293.6%) | -$2.30 M(-102.6%) | $69.50 M(+400.0%) |
| Sept 2020 | - | $87.10 M(+1753.2%) | $13.90 M(-115.0%) |
| June 2020 | - | $4.70 M(-123.5%) | -$92.90 M(-3816.0%) |
| Mar 2020 | - | -$20.00 M(-65.5%) | $2.50 M(-107.0%) |
| Dec 2019 | -$35.90 M(-104.6%) | -$57.90 M(+193.9%) | -$35.90 M(-104.4%) |
| Sept 2019 | - | -$19.70 M(-119.7%) | $807.90 M(-2.6%) |
| June 2019 | - | $100.10 M(-271.4%) | $829.30 M(+13.2%) |
| Mar 2019 | - | -$58.40 M(-107.4%) | $732.40 M(-7.1%) |
| Dec 2018 | $788.70 M(-1634.4%) | $785.90 M(>+9900.0%) | $788.70 M(-2736.1%) |
| Sept 2018 | - | $1.70 M(-46.9%) | -$29.92 M(+5.5%) |
| June 2018 | - | $3.20 M(-252.4%) | -$28.36 M(-7.9%) |
| Mar 2018 | - | -$2.10 M(-93.6%) | -$30.79 M(-40.1%) |
| Dec 2017 | -$51.40 M(+159.6%) | -$32.72 M(-1103.3%) | -$51.40 M(+281.6%) |
| Sept 2017 | - | $3.26 M(+326.3%) | -$13.47 M(-78.0%) |
| June 2017 | - | $765.00 K(-103.4%) | -$61.24 M(+31.0%) |
| Mar 2017 | - | -$22.71 M(-535.8%) | -$46.76 M(+136.2%) |
| Dec 2016 | -$19.80 M(-155.9%) | $5.21 M(-111.7%) | -$19.80 M(+96.1%) |
| Sept 2016 | - | -$44.51 M(-391.9%) | -$10.10 M(-126.9%) |
| June 2016 | - | $15.25 M(+258.7%) | $37.49 M(+30.9%) |
| Mar 2016 | - | $4.25 M(-71.5%) | $28.65 M(-19.1%) |
| Dec 2015 | $35.39 M | $14.91 M(+384.9%) | $35.39 M(+46.4%) |
| Sept 2015 | - | $3.08 M(-52.0%) | $24.17 M(+12.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2015 | - | $6.41 M(-41.8%) | $21.49 M(+26.5%) |
| Mar 2015 | - | $11.00 M(+198.1%) | $17.00 M(-91.5%) |
| Dec 2014 | $198.87 M(+2209.3%) | $3.69 M(+817.7%) | $198.87 M(-1.9%) |
| Sept 2014 | - | $402.00 K(-78.9%) | $202.69 M(-0.1%) |
| June 2014 | - | $1.91 M(-99.0%) | $202.94 M(+1.2%) |
| Mar 2014 | - | $192.87 M(+2468.2%) | $200.49 M(+2228.0%) |
| Dec 2013 | $8.61 M(-587.9%) | $7.51 M(+1060.7%) | $8.61 M(-367.9%) |
| Sept 2013 | - | $647.00 K(-219.8%) | -$3.21 M(-24.0%) |
| June 2013 | - | -$540.00 K(-154.3%) | -$4.23 M(+109.6%) |
| Mar 2013 | - | $995.00 K(-123.0%) | -$2.02 M(+14.4%) |
| Dec 2012 | -$1.76 M(-110.6%) | -$4.32 M(+1063.6%) | -$1.76 M(-170.4%) |
| Sept 2012 | - | -$371.00 K(-122.2%) | $2.51 M(-85.5%) |
| June 2012 | - | $1.67 M(+33.8%) | $17.22 M(+18.7%) |
| Mar 2012 | - | $1.25 M(-2817.4%) | $14.51 M(-12.9%) |
| Dec 2011 | $16.66 M(-297.2%) | -$46.00 K(-100.3%) | $16.66 M(-19.0%) |
| Sept 2011 | - | $14.35 M(-1483.5%) | $20.58 M(+192.4%) |
| June 2011 | - | -$1.04 M(-130.5%) | $7.04 M(-218.7%) |
| Mar 2011 | - | $3.40 M(-12.3%) | -$5.93 M(-29.8%) |
| Dec 2010 | -$8.45 M(-156.9%) | $3.87 M(+379.8%) | -$8.45 M(-158.8%) |
| Sept 2010 | - | $807.00 K(-105.8%) | $14.37 M(+748.3%) |
| June 2010 | - | -$14.00 M(-1702.1%) | $1.69 M(-89.1%) |
| Mar 2010 | - | $874.00 K(-96.7%) | $15.53 M(+4.6%) |
| Dec 2009 | $14.84 M(+65.5%) | $26.69 M(-324.9%) | $14.84 M(-265.7%) |
| Sept 2009 | - | -$11.87 M(+7050.6%) | -$8.96 M(-221.1%) |
| June 2009 | - | -$166.00 K(-188.3%) | $7.40 M(+7.8%) |
| Mar 2009 | - | $188.00 K(-93.5%) | $6.86 M(-23.5%) |
| Dec 2008 | $8.97 M(-51.5%) | $2.89 M(-35.5%) | $8.97 M(-19.8%) |
| Sept 2008 | - | $4.48 M(-740.6%) | $11.18 M(-47.0%) |
| June 2008 | - | -$700.00 K(-130.5%) | $21.11 M(-23.7%) |
| Mar 2008 | - | $2.29 M(-55.1%) | $27.68 M(+49.7%) |
| Dec 2007 | $18.49 M(-78.5%) | $5.11 M(-64.6%) | $18.49 M(+38.2%) |
| Sept 2007 | - | $14.41 M(+145.4%) | $13.38 M(-1403.2%) |
| June 2007 | - | $5.87 M(-185.1%) | -$1.03 M(-85.1%) |
| Mar 2007 | - | -$6.90 M | -$6.90 M |
| Dec 2006 | $85.83 M(-1686.5%) | - | - |
| Dec 2005 | -$5.41 M(-162.3%) | - | - |
| Dec 2004 | $8.68 M | - | - |
FAQ
- What is Emergent BioSolutions annual cash flow from financing activities?
- What is the all time high annual CFF for Emergent BioSolutions?
- What is Emergent BioSolutions annual CFF year-on-year change?
- What is Emergent BioSolutions quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Emergent BioSolutions?
- What is Emergent BioSolutions quarterly CFF year-on-year change?
- What is Emergent BioSolutions TTM cash flow from financing activities?
- What is the all time high TTM CFF for Emergent BioSolutions?
- What is Emergent BioSolutions TTM CFF year-on-year change?
What is Emergent BioSolutions annual cash flow from financing activities?
The current annual CFF of EBS is -$535.70 M
What is the all time high annual CFF for Emergent BioSolutions?
Emergent BioSolutions all-time high annual cash flow from financing activities is $788.70 M
What is Emergent BioSolutions annual CFF year-on-year change?
Over the past year, EBS annual cash flow from financing activities has changed by -$1.02 B (-211.33%)
What is Emergent BioSolutions quarterly cash flow from financing activities?
The current quarterly CFF of EBS is -$180.30 M
What is the all time high quarterly CFF for Emergent BioSolutions?
Emergent BioSolutions all-time high quarterly cash flow from financing activities is $785.90 M
What is Emergent BioSolutions quarterly CFF year-on-year change?
Over the past year, EBS quarterly cash flow from financing activities has changed by -$137.30 M (-319.30%)
What is Emergent BioSolutions TTM cash flow from financing activities?
The current TTM CFF of EBS is -$185.80 M
What is the all time high TTM CFF for Emergent BioSolutions?
Emergent BioSolutions all-time high TTM cash flow from financing activities is $829.30 M
What is Emergent BioSolutions TTM CFF year-on-year change?
Over the past year, EBS TTM cash flow from financing activities has changed by +$1.50 M (+0.80%)